A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs NDX 1017 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors M3 Biotechnology
- 18 Dec 2018 Planned number of patients changed from 92 to 100.
- 07 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 07 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.